Introduction {#section1-2055102918805187}
============

A recent Cochrane review of graded exercise therapy (GET) for chronic fatigue syndrome (CFS) concluded that GET is effective and safe ([@bibr40-2055102918805187]). The review was to determine the effects of exercise therapy for patients with CFS as compared with any other intervention or control. It included eight randomised controlled studies and reported data from 1510 participants: [@bibr22-2055102918805187] (66), [@bibr79-2055102918805187] (136), [@bibr54-2055102918805187] (148), [@bibr74-2055102918805187] (61), [@bibr49-2055102918805187] (49), [@bibr35-2055102918805187] (114), [@bibr78-2055102918805187] (296) and [@bibr84-2055102918805187] (640) (number of patients in each study between parentheses).

[@bibr40-2055102918805187] state that CFS is sometimes called myalgic encephalomyelitis (ME), but in the rest of their document, the term CFS is used. The same has been done here to avoid any confusion.

The review has been subject to criticism, for example, [@bibr38-2055102918805187] and [@bibr11-2055102918805187]. Here, we analyse the review and find seven general issues. We also identify a number of problems revealed in the original studies, including a failure to report harms. Our analysis shows the review's conclusion that GET is effective and safe is not supported by the evidence. When the objective outcomes of the trials are considered, it is possible to state that GET is ineffective for CFS.

Seven general issues {#section2-2055102918805187}
====================

1.  1. There are questions about conflicts of interest.

The review itself and seven of the eight studies ([@bibr35-2055102918805187], the exception) were conducted by researchers with an allegiance to a particular model of CFS and to two interventions, cognitive behavioural therapy (CBT) and GET.

In studies examining more than one treatment approach, the treatment favoured by the researchers tends to outperform other treatments ([@bibr42-2055102918805187], [@bibr43-2055102918805187]; [@bibr50-2055102918805187]). Several factors may contribute to this effect, but one is likely to be the manner in which the non-favoured 'comparison' treatment is conceptualised and implemented. A researcher's enthusiasm for a particular treatment can also lead his/her to overinterpret their findings or overlook limitations ([@bibr88-2055102918805187]).

Selection of the editorial group from the Cochrane Common Mental Disorders Group suggests a bias to a particular view of CFS as ME has been classified as a neurological disease by the World Health Organization (WHO) since 1969 with CFS as an equivalent. The four authors of the review are all known proponents of the biopsychosocial model, which views GET as an effective treatment for CFS.

Before they conducted their research, Fulcher (and White), Powell, Wearden, Wallman, Moss-Morris and White are all known to have favoured the approach to the illness being tested. It is notable that the one study conducted by a researcher without an allegiance to the model concluded that none of the four treatment strategies was superior to another treatment strategy in all areas ([@bibr35-2055102918805187]).

1.  2. A study was excluded, which contradicted the main findings.

[@bibr51-2055102918805187] was excluded from the Cochrane review because exercise therapy was a minor part of the intervention and it did not measure outcomes viewed as primary outcomes in the review ([@bibr40-2055102918805187]).

The trial compared multidisciplinary treatment combining CBT, GET and pharmacological treatment with usual treatment, with 1-year follow-up after the end of treatment. It concluded that at 12 months, the interventions did not improve health-related quality of life scores and led to worse physical function and bodily pain scores. Nuñez found that the combination of CBT and GET is ineffective and not evidence-based and may in fact be harmful.

1.  3. Criteria used in the trials were too broad.

As inclusion criteria, five studies ([@bibr22-2055102918805187]; [@bibr54-2055102918805187]; [@bibr79-2055102918805187], [@bibr78-2055102918805187]; [@bibr84-2055102918805187]) used the Oxford criteria. Three studies ([@bibr49-2055102918805187]; [@bibr35-2055102918805187]; [@bibr74-2055102918805187]) used the Centres for Disease Control and Prevention (CDC) criteria, also known as the Fukuda Criteria ([@bibr21-2055102918805187]).

The only requirement for the Oxford criteria ([@bibr59-2055102918805187]) is 6 months or more of unexplained fatigue. It was created as an alternative, less strict, operational definition which is essentially chronic fatigue in the absence of neurological signs with psychiatric symptoms as common associated features ([@bibr12-2055102918805187]).

The Oxford criteria are untenable because they inappropriately select healthy subjects with mild fatigue and chronic idiopathic fatigue and mislabel them as CFS ([@bibr3-2055102918805187]). The American National Institutes of Health (NIH) concluded in 2014 that the Oxford criteria are flawed and include people with other conditions, confounding the ability to interpret the science ([@bibr26-2055102918805187]). Continuing to use the Oxford definition may impair progress and cause harm ([@bibr26-2055102918805187], [@bibr27-2055102918805187]). The Agency for Healthcare Research and Quality (AHRQ) stated that using the Oxford case definition results in a high risk of including patients who may have an alternate fatiguing illness or whose illness resolves spontaneously with time ([@bibr61-2055102918805187]). Both the NIH and AHRQ recommend that the Oxford definition should be retired.

The Fukuda criteria are the most commonly used criteria for CFS. Patients need to have 6 months or more of unexplained chronic fatigue and have a minimum of four out of eight criteria. However, ME is characterised by an abnormally delayed muscle recovery after trivial exertion ([@bibr55-2055102918805187]), commonly referred to as post-exertional malaise (PEM). PEM is now accepted as a core symptom ([@bibr34-2055102918805187]) of CFS but is only optional and not compulsory for diagnosis in Fukuda as it is one of the eight additional criteria ([@bibr21-2055102918805187]). A total of 15 per cent of people labelled by these criteria as having CFS were in fact healthy people ([@bibr20-2055102918805187]).

Moreover, around 40 per cent of participants in seven of the eight studies ([@bibr74-2055102918805187], the exception with 12%) suffered from co-morbid psychiatric disorders. The presence of a medical or psychiatric condition that may explain the chronic fatigue state excludes the classification as CFS in research studies because overlapping pathophysiology may confound findings specific to CFS ([@bibr56-2055102918805187]).

The use of the Oxford and the Fukuda criteria in all eight of the studies means that they may have included patients who did not have CFS but who were susceptible to the interventions.

1.  4. Entry score requirements were not sufficiently strict.

In five studies ([@bibr22-2055102918805187]; [@bibr35-2055102918805187]; [@bibr49-2055102918805187]; [@bibr54-2055102918805187]; [@bibr79-2055102918805187]), high-functioning patients may have been included.

Three studies ([@bibr22-2055102918805187]; [@bibr35-2055102918805187]; [@bibr49-2055102918805187]) did not have entry score requirements. In two further studies, entry requirements were such that relatively high-functioning participants were included: [@bibr79-2055102918805187] had a physical functioning score of up to 83.3, and in [@bibr54-2055102918805187], patients could be selected with an almost normal physical functioning score of up to 24 (included) out of 30.

Further questions about inclusion are raised in [@bibr49-2055102918805187], where 77.6 per cent of patients were well enough to be in work, and in both [@bibr22-2055102918805187] and [@bibr49-2055102918805187], where participants had normal VO~2max~ scores.

It is likely that in five of the studies in the review patients were therefore included who may not have had CFS.

1.  5. The review used subjective fatigue measured by questionnaires as the primary outcome.

All eight trials in the review were by definition unblinded, yet the review used two subjective primary outcomes, fatigue and adverse outcomes.

Patient self-report is an unreliable measure ([@bibr81-2055102918805187]). Lack of patient blinding combined with self-reporting of outcomes leads to pronounced bias as patients become prone to outside influences leading to the erroneous inference of efficacy in its absence, thus making subjectively assessed outcomes unreliable ([@bibr33-2055102918805187]; [@bibr41-2055102918805187]). Low correlation between objective and subjective activity measurements ([@bibr58-2055102918805187]) is not confined to the chronically ill but is also present in the healthy population ([@bibr66-2055102918805187]). For patients with CFS, there is a particular problem with subjective outcomes as they may feel better able to cope with daily activities because they have reduced their expectations of what they should achieve, rather than because they have made any recovery as a result of the intervention ([@bibr86-2055102918805187]).

The review itself acknowledges this problem and states that all studies were at risk of performance bias, as they were unblinded ([@bibr40-2055102918805187]). The only way to correct for this problem in unblinded trials is by using well-designed control groups and objective primary outcomes ([@bibr17-2055102918805187]; [@bibr41-2055102918805187]). All trials in the review, apart from [@bibr54-2055102918805187], used objective outcomes, so it would have been possible for the Cochrane review to have used them.

Any conclusion that the intervention was effective must be seen as unreliable because of the use of subjective outcomes in unblinded studies.

1.  6. The Chalder Fatigue Scale is flawed.

Seven of the eight trials ([@bibr35-2055102918805187], the exception) used the Chalder Fatigue Scale to measure fatigue.

Four flaws have been identified with the use of the Scale.

First, it does not provide a comprehensive reflection of fatigue-related severity, symptomology, or functional disability in CFS ([@bibr29-2055102918805187]), as it was developed by mental health professionals, and many questions are geared towards depression and not CFS ([@bibr9-2055102918805187]).

Second, the ceiling effect means that a maximum score at baseline cannot increase even if there is deterioration during the trial. As a consequence, for example, if a participant deteriorated during the trial on eight items and improved on three, the score should reflect a deterioration of five points. However, if they had scored the maximum at baseline, then since eight scores cannot get worse and three scores have improved, the Chalder Fatigue Scale would classify the participant, who had deteriorated by five points, as improved by three points.

Analysis of the use of the Chalder Fatigue Scale in CFS patients who were well enough to attend an outpatient clinic found high rates of maximal scoring ([@bibr48-2055102918805187]). This issue was a particular concern in [@bibr78-2055102918805187]. A review of the mean and standard deviation data for that trial calculated that between 65 and 82 per cent in the pragmatic rehabilitation group (PR) must have recorded the maximum score at baseline ([@bibr64-2055102918805187]). Since the patients were more severely afflicted and unable to attend outpatient clinics, there was a high likelihood of maximum scores at baseline

Third, the Scale has been found to be unreliable in distinguishing between healthy controls and fatigue. In a trial of CBT for patients with multiple sclerosis (MS), it was found that after treatment, fatigued MS patients had less fatigue than healthy controls ([@bibr67-2055102918805187]).

Fourth, few items on the Chalder Fatigue Scale appear clearly related to fatigue and there is a focus on change in fatigue, rather than intensity ([@bibr89-2055102918805187]).

The use of the flawed Chalder Fatigue Scale to measure subjective fatigue and hence the primary outcome further casts doubt on the trial's and review's conclusions.

1.  7. There are concerns about dropouts.

The percentage of dropouts differed substantially between the trials.

Participants who do not respond to treatment or are negatively affected by it are more likely to drop out or be lost to follow up ([@bibr41-2055102918805187]). In [@bibr79-2055102918805187], 37.3 per cent dropped out in the two exercise groups combined but only 21.7 per cent in the two control groups combined. In [@bibr54-2055102918805187], 18 per cent dropped out from the exercise groups compared to only 5.9 per cent from the control group. In [@bibr49-2055102918805187], this was 12 and 0 per cent, respectively.

Only 6 per cent dropped out in the GET group of [@bibr84-2055102918805187]; however, according to the supplement to the secondary mediation paper, there were missing step test data for 34 per cent (GET) ([@bibr10-2055102918805187]), which may have inflated any improvement in the GET group on that test. These dropouts add further doubts about the reliability of the review's findings.

Analysis of the trials {#section3-2055102918805187}
======================

[@bibr22-2055102918805187] {#section4-2055102918805187}
--------------------------

The trial concluded that graded aerobic exercise is an effective treatment for CFS. Patients reported an improvement on the primary outcome (self-rated clinical global impression change score) represented by a score of 1 or 2. However, if a categorisation into 1--3 (all scores representing an improvement) and 4--7 (the rest) had been used, then there would have been no significant difference between the two treatment groups.

Because of their separate effects on fatigue, Fulcher excluded patients with a current psychiatric disorder or symptomatic insomnia, apart from simple co-morbid phobias, yet 30.3 per cent (20/66) in the trial were on full dose antidepressants. Symptomatic insomnia (sleep reversal and/or unrefreshing sleep) is a common and important symptom of CFS, so excluding such patients would seem to have excluded patients with a common symptom of CFS.

Participants in the exercise group had sessions of 5--15 minutes, increasing to a maximum of 30 minutes, at least 5 days a week. Such a workload would exclude most patients with CFS.

Doubts about the diagnosis are further cast by the VO~2max~ scores. The average VO~2max~ for healthy sedentary controls of a similar age as in the trial, 37, is 30--36 ([@bibr13-2055102918805187]). The American Medical Association (AMA) ([@bibr28-2055102918805187]) categorises impairment as follows (VO~2max~; mL/kg/min): no impairment, \>25; mild impairment, 20--25; moderate impairment, 15--20; and severe impairment, \<15. Scores for CFS patients in another study ([@bibr69-2055102918805187]) were 22.1 (mild impairment), 17.2 (moderate impairment), and 12.3 (severe impairment). In [@bibr22-2055102918805187], the VO~2max~ score at baseline in the GET group was 31.8, in other words unimpaired according to the AMA categorisation and well above even mildly impaired CFS patients in [@bibr69-2055102918805187].

The exclusion of patients with a common symptom of CFS, the inclusion of patients on full dose antidepressants, the high level of fitness of the participants and the relatively onerous workload completed by those in the exercise group raise very serious concerns about whether this was in fact a trial for patients with CFS.

[@bibr79-2055102918805187] {#section5-2055102918805187}
--------------------------

Three problems are apparent with this trial.

First, it used too broad criteria to select patients. Not only did it use the Oxford criteria, but it set a physical functioning score of \<83.3 to designate caseness and 46 per cent of participants had a current psychiatric diagnosis. Subjects randomised to graded exercise were instructed to carry out aerobic activity for 20 minutes, at least three times a week, a level of activity beyond most patients with CFS.

Second, the exercise and placebo group and its control group, the exercise control and placebo group, are difficult to compare with each other because of the big difference (30.7%) in VO~2max~ scores at baseline, 19.9 and 26.0, respectively.

Third, since more participants dropped out from and fewer complied fully with the GET groups, it would seem impossible to draw any safe conclusions. In total, 37.3 per cent dropped out of the two GET groups combined and only a small percentage (34.3%) of participants complied fully with GET. In contrast, only 21.7 per cent dropped out in the two exercise placebo groups and 78.3 per cent complied fully with exercise placebo. The difference in these two rates is particularly a concern since patients who dropped out were significantly more likely to have changed or given up their occupation as a result of their illness.

Even with these apparent biases towards the exercise groups, by 26 weeks the exercise capacity in the GET group improved by only 4.3 per cent more than in its control group. Increases of 20 per cent have been observed in patients with stable chronic heart failure after only 3 weeks of training ([@bibr47-2055102918805187]). Furthermore, the mean fatigue scores at the end of treatment in the two GET groups were 29.9 and 28.0 so that patients were still ill enough to meet the entry criteria for the trial (cut-off of 4 or more to designate caseness; 0--42).

[@bibr54-2055102918805187] {#section6-2055102918805187}
--------------------------

Similar problems afflict [@bibr54-2055102918805187]. The entry physical functioning score was \<25, a score of 25 deemed similar to normal daily functioning for the UK general population. However, the main outcome measure and predetermined criterion for clinically important improvement was a score of 25 or more or an increase of \>10 on the SF-36 physical functioning subscale (range: 10--30) 1 year after randomisation. In other words, a patient could enter the trial with a score of 24, improve to 25 over the course of the trial, and this minimal improvement would be deemed clinically important.

The trial employed non-equivalent controls which favoured the interventions. A minimum number of sessions were stipulated for the treatment groups: 3 hours face-to-face and 1 hour telephone contact for the minimum intervention group, 3 hours face-to-face and 4.5 hours telephone contact for the telephone intervention group and 10 hours face-to-face and 1.5 hour telephone contact for the maximum intervention group. There was no such specification for the control group. It is possible those in the control group had zero hours of contact and it was therefore no more than a waitlist group. This was recognised in the article where it is acknowledged that one of the limitations was the lack of a placebo control group that received equivalent therapist time and attention.

The hospital anxiety and depression scale scores suggest that instead of treating the CFS, the interventions addressed the patients' depression. At baseline, patients had high depression (9.3, 9.0 and 9.0) and anxiety scores (10.6, 10.0 and 10.2) for the minimum intervention, telephone intervention and maximum intervention groups, respectively. One year after randomisation, the depression scores improved dramatically to 4.2, 4.6 and 4.2, and the anxiety scores less so to 7.1, 6.5 and 7.7. In the control group, however, the scores remained roughly the same: 10.4 and 10.1 for depression and 11.2 and 10.1 for anxiety, at baseline and 1 year after randomisation, respectively.

Once again, there was a problem with selection criteria, 33.8 per cent (50/148) of the participants were working at the start of the trial and dropouts. The dropout rate was 16.2 per cent (6/37) for the minimum intervention, 18 per cent (7/39) for the telephone intervention and 18.4 per cent (7/38) for the maximum intervention. In contrast, the control group dropout rate was much lower at 5.9 per cent (2/34).

These flaws make any conclusion that the interventions were effective impossible.

[@bibr74-2055102918805187] {#section7-2055102918805187}
--------------------------

Despite its claim to show graded exercise improves functional ability and minimises deconditioning, which can result in more symptoms, and that these improvements may be associated with the abandonment of avoidance behaviours, it would appear that the trial was not of graded exercise but of a form of pacing.

In graded exercise therapy for CFS, planned physical activity and not symptoms dictate what participants do ([@bibr4-2055102918805187]). Participants in this trial, though, were instructed to exercise every second day, unless they had a relapse. If this occurred, or if symptoms became worse, the next exercise session was shortened or cancelled. Subsequent exercise sessions were reduced to a length the patient felt manageable.

Since the exercise treatment allowed patients to decrease as well as increase how much exercise they did, depending on their symptoms, the intervention being evaluated was in fact not GET but a form of pacing ([@bibr25-2055102918805187]).

[@bibr49-2055102918805187] {#section8-2055102918805187}
--------------------------

This trial had a biased sample: participants were from a private clinic and had contacted the university, so were self-selected. They were, then, invested in the trial and more likely to believe in the possible effectiveness of the interventions. Furthermore, patients were high functioning: only 22.4 per cent were unemployed and unable to work due to disability, indicating 77.6 per cent were employed and therefore only mildly affected. As many as 30 and 42 per cent of the sample, though, were possibly suffering from depression and anxiety, respectively.

The groups were poorly matched: there was a difference in mean ages (36.7 in the GET group, 45.5 in the SMC control), illness duration (2.67 years GET, 5.0 years SMC) and SF-36 physical functioning scores (53.10, GET; 45.65 SMC) at baseline.

Although it was concluded that graded exercise appears to be an effective treatment for CFS, patients showed no objective improvement. In fact, there was a significant physical deterioration after 'effective' GET as seen in the large drop in VO~2max~ of 15 per cent. Since there is an inverse relation between fatigue and activity ([@bibr57-2055102918805187]), a decrease in fatigue should have been matched by an objective increase in physical functioning.

The study acknowledges that the intervention (GET) did not have a significant effect on fitness. Any conclusions, then, about the effectiveness of the treatment cannot be sustained.

[@bibr35-2055102918805187] {#section9-2055102918805187}
--------------------------

The review says this trial showed little or no difference in fatigue between anaerobic exercise and treatment as usual at follow-up. It states that the better physical functioning scores for relaxation therapy were because the relaxation group (RELAX) had a higher mean score at baseline than the anaerobic activity group (ACT), 53.77 and 39.17, respectively. However, the objective 6-minute walk test results at baseline were similar: 1335 (ACT) versus 1317 (RELAX; higher scores indicating better outcome). The physical functioning scores did improve more for the RELAX group: an increase of 12.1 per cent from baseline for RELAX, compared to 1.4 per cent for ACT.

In other tests, the RELAX group also performed better. Improvement in the 6-minute walk test was 3.2 per cent (ACT) and 8.4 per cent (RELAX), and in quality of life scores 3.5 per cent (ACT) and 12.3 per cent (RELAX). The RELAX group performed better for difference in symptom outcome, improvement for muscle pain, unrefreshing sleep and PEM.

The trial would seem to show, contrary to the conclusion in the review, that participants in the relaxation group improved more than those in the exercise group.

[@bibr78-2055102918805187] {#section10-2055102918805187}
--------------------------

There were once again problems with entry requirements for this trial: Criteria included 70 (out of 100) or lower on the SF-36 physical functioning scale, but one patient was admitted to the trial with a score of 75; 20.3 per cent (60/296) of the participants suffered from anxiety and 17.9 per cent (53/296) from depression.

The trial was not properly controlled. The PR group on average received 11.63 sessions (9.63 with the therapist + 2 general practitioner (GP) consultations), the supportive listening group (SL) had 12.5 (9.5 + 3 GP consultations) and the treatment as usual (GPTAU) control group had only three GP consultations.

The entry criteria and outcomes were switched after the trial had started. Dates for the trial are given as from 21 June 2004 to 25 July 2008 in the protocol registered with the International Standard Randomised Controlled Trials Number (ISRCTN). The selection criteria were changed in February 2005, from the Fukuda to the even wider Oxford criteria. No reason was given ([@bibr75-2055102918805187]).

According to the FINE trial protocol ([@bibr80-2055102918805187]), primary outcomes were to be self-reported physical functioning and fatigue at 1 year. Yet in the 2010 paper, the measures were taken instead at the end of treatment, 20 weeks and 70 weeks from recruitment.

The step test was an objective secondary outcome measure in the protocol but was omitted from the 2010 paper. Not publishing results jeopardises the validity of a study ([@bibr31-2055102918805187]). The results were published 3 years later ([@bibr76-2055102918805187]), and there were no differences between pragmatic rehabilitation and GP treatment. Three Dutch studies that also did not publish their step test results on analysis many years later by proponents of the biopsychosocial model also showed no objective differences between treatment and control ([@bibr87-2055102918805187]).

The fatigue scores were changed from bimodal (0--11) to Likert (0--33) in a Rapid Response in the BMJ ([@bibr77-2055102918805187]) and in [@bibr76-2055102918805187]. Re-scored there was now a clinically modest, but statistically significant effect of PR compared with GPTAU at both outcome points. However, altering measures in this way after the trial to find a small effect suggests a form of p-hacking.

The entry criteria, outcome switching and null objective improvement in this trial mean that it is unsafe to claim any effect for the interventions.

[@bibr84-2055102918805187] {#section11-2055102918805187}
--------------------------

This trial was the largest, 640 patients in a review that included 1510. A number of similar flaws have been identified.

Patients were included with depression or anxiety: 47 per cent of participants had a co-morbid depression or anxiety disorder and only 20 per cent (640/3158) of participants screened were selected for the study.

The control group did not have the same contact hours: the CBT group received on average 16 sessions, the GET group 17 sessions (both including three sessions of SMC), yet the SMC group only had five. This imbalance creates serious biases towards finding a positive effect for the intervention, regardless of whether it is effective or not ([@bibr41-2055102918805187]).

A null effect at long-term follow-up was spun as positive. Outcomes with SMC alone or adaptive pacing therapy (APT) improved from the 1-year outcome and were similar to CBT and GET at long-term follow-up, but it was claimed that the data should be interpreted in the context of additional therapies having being given after the 1-year trial final assessment ([@bibr60-2055102918805187]). However, the long-term follow-up (Supplementary Appendix) shows the majority of participants did not have any additional CBT (76%) or GET (83%) after the trial. It also shows that patients in all four groups who did not receive additional treatment subsequent to trial completion exhibited lower fatigue and higher physical functioning scores relative to those of patients who received additional treatment ([@bibr71-2055102918805187]).

Baseline figures were used for one objective test, an actometer, a reliable measure of activity to assess improvement objectively ([@bibr58-2055102918805187]), but were not recorded at the end of the trial. The reason given was that it would be too great a burden ([@bibr71-2055102918805187]) for patients, even though they had consented to use it; they had completed moderately effective treatment ([@bibr84-2055102918805187] and 22 per cent of those in the CBT and GET groups had recovered ([@bibr83-2055102918805187]).

An extensive number of endpoint changes were made ([@bibr60-2055102918805187]; [@bibr71-2055102918805187]; [@bibr84-2055102918805187]; [@bibr90-2055102918805187]). The timing of these changes -- several months after trial completion -- was highly problematic ([@bibr90-2055102918805187]). As a result, there was an overlap in entry and recovery criteria: 13.3 per cent of participants were already recovered according to one (12.8%) or two (0.5%) of the recovery criteria at trial entry ([@bibr72-2055102918805187]).

These changes affected both the physical functioning scores and the fatigue scores. The minimum physical functioning score required to qualify as recovered was reduced from 85 to 60 ([@bibr84-2055102918805187]). The maximum score for trial entry was increased from 60 to 65 (0--100; higher scores indicating better functioning), although according to the PACE trial's recovery article, a score of 65 or less represents 'abnormal levels of physical function' ([@bibr83-2055102918805187]) and severe disability according to the literature ([@bibr65-2055102918805187]). Participants with a score of 60--65 (inclusive) were thus considered ill enough to participate and to have an abnormal level of physical functioning, yet were also recovered and severely disabled. Three participants (0.45%) saw their physical functioning score go down from 65 to 60, reflecting deterioration, and three others (0.45%) had unchanged physical functioning scores, but all (0.9%) were still classed as recovered, according to the physical functioning recovery criterion ([@bibr73-2055102918805187]).

Something similar happened to the fatigue scores. When PACE was registered with the ISRCTN on 22 May 2003, participants needed a Chalder Fatigue Questionnaire (CFQ) score of 4 or more to be classed as ill enough to take part ([@bibr82-2055102918805187]). The CFQ entry criterion was changed to six or more before the trial started and then during an unblinded trial switched from bimodal to Likert, 18 or more to qualify. To be classed as recovered, a bimodal score of ⩽3 out of 11, which represented a screening threshold for abnormal fatigue, was changed to a Likert score of 18 or less (0--33) ([@bibr83-2055102918805187]). Consequently, with a Likert score of 18, one was simultaneously classed as disabled and recovered.

These endpoint changes increased recovery rates of CBT and GET fourfold. Had the PACE trial stuck to the protocol defined endpoints, then there would have been no statistically significant difference in recovery rates between the four treatment groups ([@bibr90-2055102918805187]).

The net improvement of the quality of life scores (EQ-5D) after GET at 52 weeks over the adaptive pacing control group was 1 per cent (13.5% (0.07/0.52)--12.5% (0.06/0.48)). A study by [@bibr52-2055102918805187] of 20,220 adult patients found a mean quality of life score of 0.84 for the total population and 0.93 for people without a chronic condition. Yet the quality of life at 52 weeks in the GET group (0.59) ([@bibr44-2055102918805187]) was similar to the score (0.60) for people with five or more chronic health conditions and still worse than in cerebral thrombosis (0.62), rheumatoid arthritis and angina (0.65), acute myocardial infarction (AMI) (0.66) ([@bibr52-2055102918805187]), MS (0.67), lung cancer (0.69), stroke (0.71) or ischaemic heart disease (0.72) (higher scores indicating a better quality of life) ([@bibr19-2055102918805187]).

Also, there was no statistically significant difference in the improvement in CFS symptom count between GET and SMC (p = 0.0916) or APT (p = 0.23) at 52 weeks.

These flaws in both the review and the trial render unsafe any conclusion that GET is effective.

Evidence on harms {#section12-2055102918805187}
=================

According to the review, only two studies reported on safety or adverse reactions and in the larger ([@bibr84-2055102918805187]) there are questions about the definition used.

The review acknowledges that limited information makes it difficult to draw firm conclusions about the safety of exercise therapy yet claims no evidence to suggest exercise therapy may worsen outcomes. This conclusion relies on the fact that [@bibr84-2055102918805187] reported only two serious adverse reactions (SARs) possibly related to treatment, and [@bibr78-2055102918805187] reported no SARs due to therapy.

However, the claims that the interventions in [@bibr84-2055102918805187] are safe are based on an unrealistic definition of harms. Adverse events were considered serious when they involved death, hospital admission, increased severe and persistent disability, self harm, were life-threatening or required an intervention to prevent one of these ([@bibr84-2055102918805187]). These are not harms normally complained of by patients.

Furthermore, reports in both [@bibr49-2055102918805187] and [@bibr79-2055102918805187] raise concerns. [@bibr49-2055102918805187] found that for 40 per cent of participants exercise led to worsening of symptoms. 12 per cent dropped out from the GET group yet 0 per cent from the control group.

In [@bibr79-2055102918805187], only 34.3 per cent of participants complied fully with GET compared to 78.3 per cent who complied fully with the control group treatment, pacing. 37.3 per cent dropped out of the two graded exercise treatment groups combined, while only 21.7 per cent dropped out of the two control groups combined. Patients who dropped out were significantly more likely to have changed or given up their occupation as a result of their illness ([@bibr79-2055102918805187]). A treatment cannot be considered safe if patients do not actually adhere to it ([@bibr39-2055102918805187]).

Caution about the safety of GET is particularly necessary given the consistent finding in patient surveys that the intervention has caused worsened health in a large percentage of patients ([@bibr1-2055102918805187]; Action for ME, 2011; [@bibr6-2055102918805187]; [@bibr7-2055102918805187]; [@bibr14-2055102918805187]; [@bibr15-2055102918805187]; [@bibr18-2055102918805187]; [@bibr24-2055102918805187]; [@bibr37-2055102918805187], [@bibr39-2055102918805187]; [@bibr45-2055102918805187], [@bibr46-2055102918805187]). For example, in a survey by [@bibr2-2055102918805187], 60.2 per cent of people with ME reported that GET had made their condition worse, 44.1 per cent reported that it had made it much worse or very much worse. The [@bibr46-2055102918805187] found that in 74 per cent, GET had made their condition worse. In 82 per cent of patients who were housebound or bedridden, their health had been negatively affected by GET and some patients were not severely affected before trying GET ([@bibr1-2055102918805187]).

It has also been shown that patients have a low tolerance for physical activity or mild exercise, which can provoke symptoms ([@bibr62-2055102918805187]; [@bibr70-2055102918805187]) and the experiences of harm from GET by CFS patients are well supported by the scientific literature ([@bibr68-2055102918805187]).

Furthermore, GET protocols indirectly discourage research participants from reporting harm. A key feature of GET is pushing beyond limits and participants are told to interpret symptom flares experienced during a study as a normal exercise response and reconditioning ([@bibr4-2055102918805187]). The GET manual may instruct patients to view negative experiences as unhelpful ([@bibr85-2055102918805187]) or they may be told that 'Activity or exercise cannot harm you' ([@bibr53-2055102918805187]).

The failure of most studies to report on safety or adverse reactions and the unrealistic definition used by [@bibr84-2055102918805187] mean that it is not possible to conclude GET is safe.

Review of the objective outcomes {#section13-2055102918805187}
================================

Analysis shows the review's conclusion that GET is effective and safe is not justified by the evidence. It is worth attempting to see whether anything can be properly inferred from the trials. Objective outcomes reveal GET to be ineffective.

It is worth noting that the GET model is at odds with the physiological findings ([@bibr30-2055102918805187]). Physical deconditioning does not seem to be a perpetuating factor in CFS ([@bibr5-2055102918805187]) and CFS patients without a co-morbid psychiatric disorder do not have an exercise phobia ([@bibr23-2055102918805187]).

[@bibr54-2055102918805187] did not use objective outcomes. The seven other trials that did use objective outcomes, only [@bibr22-2055102918805187] (6.9%) and [@bibr79-2055102918805187] (4.3%), showed a minimal improvement in the intervention group compared to the control. However, there are reasons to consider this minimal benefit with caution. Both trials used the broad Oxford criteria, had a high percentage of participants with a psychiatric disorder and failed to exclude very high-functioning participants. [@bibr22-2055102918805187] had no entry score requirements so that participants were selected with a normal VO~2max~ score and no impairment according to the AMA, and in [@bibr79-2055102918805187], participants could have a physical functioning score of up to 83.3.

A large number of patients were excluded from [@bibr22-2055102918805187] (60.5%), which used a walking test to measure improvement. It is possible that patients concentrated on the exercise and slightly increased walking at the expense of other areas of their life. In [@bibr79-2055102918805187], a higher percentage of participants dropped out of exercise (37.3%) compared to the control groups (21.7%).

Even then, the difference in improvement in the exercise groups was only 4--7 per cent. Increases of 20 per cent have been observed in patients with stable chronic heart failure after only 3 weeks of exercising ([@bibr47-2055102918805187]). A major criterion for defining CFS is a reduction in physical capacity of at least 50 per cent compared to pre-illness levels ([@bibr13-2055102918805187]; [@bibr21-2055102918805187]; [@bibr32-2055102918805187]) so an improvement of 4--7 per cent would still leave patients considerably worse off than before the illness.

In [@bibr74-2055102918805187], although the oxygen uptake values (VO~2max~) were 9.6 per cent higher after the intervention in the exercise group, the difference in final values for the groups was not significant and the activity levels did not differ between the groups.

[@bibr49-2055102918805187] found no statistically significant group effect for the physiological variables, including the maximum heart rate achieved, the percentage of the predicted maximum heart rate and the VO~2max~. The intervention (GET) did not have a significant effect on fitness; in fact, there was a large drop in VO~2max~ of 15 per cent.

In the 6-minute walk test in [@bibr35-2055102918805187], the ACT group improved by 3.2 per cent, yet patients in the relaxation control group improved by 5.2 per cent more, an improvement matched in the quality of life scores (3.5%, ACT; 12.3%, RELAX), symptom outcome improvement for muscle pain, unrefreshing sleep and PEM.

When the scores for the only objective outcome used in [@bibr78-2055102918805187], the step test, were published in 2013, there were no differences between the pragmatic rehabilitation and GP treatment as usual groups on any of the step test measures at 20 or 70 weeks.

An even larger number of patients were excluded from [@bibr84-2055102918805187] (79.7%). Their step test did not show any objective improvements. This is matched by the net improvement of the quality of life scores after GET over APT of only 1 per cent. The number of patients who were unable to work and who were receiving benefits increased and the number of patients receiving income protection in the GET group actually doubled. In addition, there was no statistically significant difference in the improvement in CFS symptom count between GET and SMC (p = 0.0916) or APT (p = 0.23) at 52 weeks.

There was a slight benefit shown in the 6-minute walk test after exercise for 24 weeks. Patients with stable chronic heart failure improved their 6-minute walk test results by 65 per cent after only 3 weeks of exercising ([@bibr47-2055102918805187]). Also, since the actometers were used at the beginning of the trial but not after 'effective' treatments, as with [@bibr22-2055102918805187], it is not known whether patients concentrated on the exercise and slightly increased walking at the expense of other areas of their life. This doubt is all the greater since despite exercising five times a week with a target of 30 minutes a time for 24 weeks, the fitness levels of those in the GET group did not improve. This suggests that there was an underlying physical problem preventing this.

Even after the slight improvement measured on the walk test, patients would still be ill enough to be put on the waiting list for a lung transplant. No one in the trial achieved actual recovery, where symptoms are eliminated and patients return to pre-morbid levels of functioning ([@bibr36-2055102918805187]), which is the general public's understanding of the meaning of recovery ([@bibr72-2055102918805187]). The PACE trial protocol defined improvement as an increase of 50 per cent. According to the 6-minute walk test results, the only objective individual results that were released, this benchmark was matched by 6.3 per cent in the GET group, but also 5 per cent in the SMC group, implying an effect of GET of only 1.3 per cent (2/160) as participants in all treatment groups also received SMC ([@bibr72-2055102918805187]).

The trial omitted from the review, [@bibr51-2055102918805187], found that at 12 months the intervention did not improve health-related quality of life scores and led to worse physical function and bodily pain scores. They also concluded that the combination of CBT and GET is ineffective and not evidence-based and may in fact be harmful.

[@bibr63-2055102918805187] analysed the effectiveness of CBT and GET in the Belgian CFS knowledge centres. They found no objective improvements after CBT and GET (VO~2max~) and fewer people were able to work and more people were receiving illness benefits.

Two American government agencies, the [@bibr8-2055102918805187]) and the AHRQ ([@bibr61-2055102918805187]), have recently removed (CDC) and downgraded (AHRQ) their recommendations for CBT and GET, because there is insufficient evidence that GET is effective. The [@bibr16-2055102918805187] has removed its recommendation for GET in March 2018 for the same reason.

Conclusion {#section14-2055102918805187}
==========

The GET trials reviewed here are inherently biased: use of exercise may attract only the mildly affected and may deter the more disabled patients from participating. These trials go back for more than two decades, at the cost of considerable money and involving large numbers of patients. The flaws in the review and the trials, as discussed above, all created a bias in favour of the exercise intervention. Despite these flaws, they have found no significant evidence of objective improvement. The analysis of the objective outcomes in the trials provides sufficient evidence to conclude GET is an ineffective treatment for ME/CFS.

Most studies failed to report on safety or adverse reactions, and [@bibr84-2055102918805187], one of the two studies that did, used an unrealistic definition. ME is characterised by an abnormally delayed muscle recovery after trivial exertion ([@bibr55-2055102918805187]), commonly referred to as PEM. Exercise physiology studies reveal abnormalities in patients' responses to exertion. Yet PEM is not a requirement for diagnosis according to the Oxford criteria, used by five of the studies, and only an optional criterion according to the Fukuda criteria, used by the other three studies in the review. If patients do not suffer from PEM, it is likely that they will have no problems exercising. This might be an important reason why outside of clinical trials things are different with many patients, who do suffer from PEM, reporting deterioration with GET. Given these considerations, one cannot conclude that GET is safe.
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